MedTrace Logo

Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients With Apparent Risk Factors of NASH

NCT05343780 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2022-04-25

No results posted yet for this study

Summary

A Phase II, Randomized, Double Blind, Placebo-Controlled Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients with Apparent Risk Factors of Nonalcoholic Steatohepatitis (NASH)

Conditions

Interventions

DRUG

Heptex

Dukung Anak 200 mg + Milk thistle 100 mg

OTHER

Rice bran

Placebo

Sponsors & Collaborators

  • Ain Shams University

    collaborator OTHER

  • National Hepatology & Tropical Medicine Research Institute

    collaborator OTHER_GOV

  • Natural Wellness Egypt

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-08
Primary Completion
2022-02-21
Completion
2022-02-21

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05343780 on ClinicalTrials.gov